
We are very happy to announce that Kancera will collaborate with the Nordic Society of Gynaecological Oncology in our upcoming ovarian cancer study!
“Women with far progressed ovarian cancer that experience relapse from platinum chemotherapy has very few treatment options left. The opportunity for KAND567 to restore platinum sensitivity is, even though at an early stage, very interesting. We are very enthusiastic about the opportunity to support Nordic biotech to potentially develop a new treatment option for these patients.”, says Dr. Mansoor Raza Mirza, Medical Director and head of the NSGO-CTU.